A Phase 2 interventional study of SHR-A1904 for Injection in Biliary Tract Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Biliary Tract Neoplasms with a site in China — 93 open to participants now, 111 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.
Among the 176 studies in Biliary Tract Neoplasms with a site in China, this one is the 39th largest by planned enrollment of the 157 interventional ones that give a count, is one of 33 that started in 2026, is one of 94 in phase 2, reaches primary completion later than 110 of the 110 other live ones, and was the 143rd registered.
519 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.
Browse Biliary Tract Neoplasms studies →93 of the 176 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Haitao Zhao, MD · Sites in China
Ages 18–75
Haitao Zhao, MD · Sites in China
Ages 18–80
Haitao Zhao, MD · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 123 · Phase 3 18 · Phase 4 2
First in 1997; this study’s year is marked. 33 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 151 is above the median of 58 across 429 interventional studies indexed under Biliary Tract Neoplasms.
Median enrollment 62 across the 157 interventional studies, 200 across the 19 observational. Of the 32 that completed or were terminated, 5 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 176 have an industry lead sponsor. The 10 most frequent:
This study is registered under Suzhou Suncadia Biopharmaceuticals Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 6 studies filed under Biliary Tract Neoplasms — fewer than ten, so there is no comparison to draw.
39 of the studies in Biliary Tract Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06219941AstraZenecaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | 2026-11-17 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT07911397Beijing Tsinghua Chang Gung HospitalProspective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT | 2026-11-30 |
| NCT04900818I-Mab Biopharma US LimitedStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | 2026-12 |
| NCT06792435Astellas Pharma Global Development, Inc.XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | 2026-12-30 |
Add all 39 to your calendar (.ics) → With an account.
Among the 176 studies in Biliary Tract Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SHR-A1904 for injection, low dose.
Drug: SHR-A1904 for Injection
SHR-A1904 for injection, high dose.
Drug: SHR-A1904 for Injection
SHR-A1904 for injection, different doses.
Objective response rate (ORR) assessed by investigator.
Phase IIa.
Time frame: Until progression, assessed up to approximately 1 year.
Disease control rate (DCR) assessed by investigator.
Phase IIa/IIb.
Time frame: Approximately 1 year.
Duration of objective tumor response (DoR) assessed by investigator.
Phase IIa/IIb.
Time frame: Approximately 1 year.
Time to response (TTR) assessed by investigator.
Phase IIa/IIb.
Time frame: Approximately 1 year.
Progression-free survival (PFS) assessed by investigator.
Phase IIa/IIb.
Time frame: Approximately 1 year.
Overall survival (OS).
Phase IIa/IIb.
Time frame: Approximately 2 years.
Adverse events (AEs).
Phase IIa/IIb.
Time frame: Until study completion, assessed up to approximately 1 year.
Serious adverse events (SAEs).
Phase IIa/IIb.
Time frame: Until study completion, assessed up to approximately 1 year.
Immunogenicity indicators of SHR-A1904: drug resistant antibody (ADA).
Phase IIa/IIb.
Time frame: Approximately 6 months.
Immunogenicity indicators of SHR-A1904: neutralizing antibody (NAb).
Phase IIa/IIb.
Time frame: Approximately 6 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2030, 57 months after the start.
Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's planned 57 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garetatug rezetecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd. →